Physician profile
Rachel E Lessor
NPI 1275054538
$6,812.04
in general payments reported to CMS, 2019-2025
39 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,840 · 2022: $1,061 · 2023: $829 · 2024: $1,509 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,911.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.35 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $966.45 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $559.06 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Viiv Healthcare Company | $522.57 | 2021-2025 | Apretude, Dovato, Cabenuva |
| Vanda Pharmaceuticals INC. | $373.98 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $323.41 | 2021-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $283.72 | 2021-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $227.43 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $222.84 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $210.06 | 2021-2023 | Spravato |
| Novo Nordisk INC | $172.62 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Indivior INC. | $158.64 | 2022-2024 | Sublocade |
| Sunovion Pharmaceuticals INC. | $129.32 | 2021 | |
| Qol Medical, LLC | $123.73 | 2024 | Sucraid |
| Astellas Pharma US INC | $119.67 | 2021-2025 | Veozah |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Lessor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.